BPC November 17 update

Rockwell RMTI Drug interaction data; Cyclo CYTH Pricing of offering

Pre-Market Updates

Rockwell Medical, Inc. (NASDAQ: RMTI) announced the publication of results in the Journal of Bioequivalence & Bioavailability from a study designed to investigate the co-administration of intravenous (IV) Ferric Pyrophosphate Citrate with unfractionated heparin (UFH) as an admixture via the HD-machine syringe pump. The study demonstrated no clinically relevant drug-drug interaction between FPC and UFH on the effects of UFH nor on the ability of FPC to deliver bioavailable iron when these agents are co-administered.

Cyclo Therapeutics, Inc. (NASDAQ: CYTH) announced the pricing of its public offering of 1,950,000 shares at $6.00 per share. Gross proceeds from the offering are to be $11.7 million.

Atea Pharmaceuticals (NASDAQ: AVIR) announced during after-hours yesterday that its "strategic collaboration" with Roche Holding AG (OTC: RHHBY) for the development of AT-527 to treat COVID-19 will be terminated February 10, 2022. The rights and licenses granted to Roche will be returned to Atea.

GlaxoSmithKline plc (NYSE: GSK) and Vir Biotechnology, Inc. (NASDAQ: VIR) announced US government contracts totaling approximately $1 billion to purchase sotrovimab, a treatment for COVID-19.

Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX) released top-line results from its Phase 2 trial of ELX-02 to treat cystic fibrosis (CF). ELX-02 was well-tolerated and achieved a statistically significant 5.4mmol/L reduction in sweat chloride in patients at the1.5mg/kg/day dose.

SVB Leerink initiated coverage on Xeris Biopharma Holdings (NASDAQ: XERS) with an Outperform rating and announced a price target of $6.

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) announced the pricing of a public offering of 4,027,273 shares at $13.75 per share and to certain investors in place of common stock, pre-funded warrants to purchase up to an aggregate of 3,272,727 shares of its common stock at $13.74 per each pre-funded warrant. The aggregate gross proceeds from this offering are to be approximately $100.3 million.

Pre-Market Advancers

CompanyPriceChange
PTN
Palatin Technologies Inc.
$0.79+0.2324  +41.68%
STSA
Satsuma Pharmaceuticals Inc.
$5.96+0.71  +13.52%
BYSI
BeyondSpring Inc.
$16.25+1.9  +13.24%
ACHL
Achilles Therapeutics plc
$5.39+0.55  +11.36%
OGEN
Oragenics Inc.
$0.60+0.0488  +8.87%
DRMA
Dermata Therapeutics Inc.
$2.93+0.23  +8.52%
UNCY
Unicycive Therapeutics Inc.
$3.16+0.24  +8.22%
WDNA
WisdomTree BioRevolution Fund
$26.00+1.8493  +7.66%
LOGC
LogicBio Therapeutics Inc.
$3.15+0.21  +7.14%
URGN
UroGen Pharma Ltd.
$13.00+0.86  +7.08%

Pre-Market Decliners

CompanyPriceChange
NAVB
Navidea Biopharmaceuticals Inc.
$1.15-0.15  -11.54%
IKT
Inhibikase Therapeutics Inc.
$1.91-0.15  -7.28%
PSTI
Pluristem Therapeutics Inc.
$2.52-0.17  -6.32%
BPTS
Biophytis SA
$5.40-0.36  -6.25%
APVO
Aptevo Therapeutics Inc.
$12.26-0.81  -6.20%
ANGN
Angion Biomedica Corp.
$3.54-0.2099  -5.60%
PBLA
Panbela Therapeutics Inc.
$1.86-0.11  -5.58%
VLON
Vallon Pharmaceuticals Inc.
$5.05-0.26  -4.90%
RVPH
Reviva Pharmaceuticals Holdings Inc.
$3.60-0.18  -4.76%
CRNX
Crinetics Pharmaceuticals Inc.
$23.25-1.15  -4.71%